DICE Therapeutics to Present at November Investor Conferences

Rhea-AI Summary

DICE Therapeutics, a biopharmaceutical company focused on innovative oral therapeutics for chronic diseases, will participate in two investor conferences this November. Management will present at the 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22 at 10:00 a.m. ET, followed by a session at the 4th Annual Evercore ISI HealthCONx Conference on November 30 at 3:55 p.m. ET. Webcasts of both events will be available on the company's website. DICE is advancing oral candidates targeting significant immunology pathways, including IL-17, for enhanced therapeutic outcomes.

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will participate in the following investor conferences in November:

• 33^rd Annual Piper Sandler Virtual Healthcare Conference. A pre-recorded fireside chat with DICE management will be available on Monday, November 22 at 10:00 a.m. ET.
• 4^th Annual Evercore ISI HealthCONx Conference 2021. Management will participate in a fireside chat on Tuesday, November 30 at 3:55 p.m. ET.

Live and archived webcasts of the presentations will be accessible under “Events & Presentations” in the Investors section of the company's website.

About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Contact:
Katie Engleman, 1AB
katie@1abmedia.com

FAQ

What conferences will DICE participate in during November 2021?

DICE will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22 and the 4th Annual Evercore ISI HealthCONx Conference on November 30.

What is the timing of DICE's presentations at the investor conferences?

DICE's presentation at the Piper Sandler Conference is scheduled for November 22 at 10:00 a.m. ET, and at the Evercore ISI Conference on November 30 at 3:55 p.m. ET.

How can I access DICE's conference presentations?

Live and archived webcasts of DICE's presentations will be available in the 'Events & Presentations' section of their website.

What is the focus of DICE Therapeutics' research?

DICE Therapeutics focuses on developing oral therapeutics for chronic diseases, particularly targeting IL-17 and integrins related to immunology.

What is DICE's lead therapeutic candidate?

DICE's lead candidate is S011806, an oral antagonist of IL-17, targeting chronic diseases in immunology.